Bioreactor Expansion

Description

The client aimed to increase the capacity of their existing drug substance manufacturing facility located at their Fremont campus. The company required a design and installation for a new 12K Bioreactor at East Train, 3000L Media Feed Tank, and a Centrifuge for upstream process.

IPS joined architects, engineers, and subcontractors—including electrical, plumbing, fire and life safety, concrete, and more—into one centralized building information modeling (BIM) command center located in the project field office. As the models were created, each subcontractor was able to add respective components to the project while still being in direct collaboration with other subcontractors.

IPS managed the programming, design, and construction of the project. Key design consultants and the construction team developed the functional design brief and concept design. This project included manufacturing processes, central utilities plant (ex. WFI, boiler, steam, waste, and electrical), as well as the architectural/structural renovation of the existing building. IPS completed a process simulation tool to identify all bottlenecks both upstream and downstream.

The site now holds a new ISO-8 cell culture area where the bioreactor and the media feed tank were installed. This was done in the existing hallway at the center of the building’s first and second floors. Though operations continued at BI, the layout helped construction minimize the time and risk for final implementation and eventually tie-in a facility shutdown.

IPS’s innovative safety processes led to zero incidents of significance on the project.

Project Details

LOCATION

Fremont, CA

MARKET

Biotech & Pharma

PROJECT SIZE

25,000 sf

SERVICES
  • Engineering Peer Review
  • Construction Management
  • Construction Coordinators
KEY SYSTEMS
  • DI/WFI
  • Clean Steam
  • Media Transfer
  • CIP
  • Cleanroom
  • Bioreactors

Company Profile

The client is one of the world’s largest pharmaceutical companies. The private company is known for its development of drug treatments related to cancer, respiratory diseases, immune system diseases, and diseases of the central nervous system.